Evidence map›Paper›PMID 38729941›Full record

SynthesisNutrition & diabetes2024

The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review.

Azin Vakilpour, Ehsan Amini-Salehi, Arman Soltani Moghadam, Mohammad-Hossein Keivanlou, Negin Letafatkar, Arman Habibi, Mohammad Hashemi, Negar Eslami, Reza Zare, Naeim Norouzi and 5 more

Erratum issuedAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Nutrition & diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Azin Vakilpour *Guilan University of Medical Sciences, Rasht, Iran.
Ehsan Amini-Salehi *Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Arman Soltani MoghadamTehran University of Medical Sciences, Tehran, Iran.
Mohammad-Hossein KeivanlouGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.ORCID http://orcid.org/0000-0002-5305-1288
Negin LetafatkarGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Arman HabibiGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Mohammad HashemiStudent Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Negar EslamiGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Reza ZareStudent Research Committee, Larestan University of Medical Sciences, Larestan, Iran.
Naeim NorouziGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Hamed DelamStudent Research Committee, Larestan University of Medical Sciences, Larestan, Iran.
Farahnaz JoukarGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Fariborz Mansour-GhanaeiGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Soheil HassanipourGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. Soheil.epid@gmail.com.
Sandeep Samethadka NayakDepartment of Internal Medicine, Yale New Haven Health Bridgeport Hospital, Bridgeport CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (T2DM) is a significant risk factor for non-alcoholic fatty liver disease (NAFLD). Increased fasting blood sugar (FBS), fasting insulin (FI), and insulin resistance (HOMA-IR) are observed in patients with NAFLD. Gut microbial modulation using prebiotics, probiotics, and synbiotics has shown promise in NAFLD treatment. This meta-umbrella study aimed to investigate the effects of gut microbial modulation on glycemic indices in patients with NAFLD and discuss potential mechanisms of action.

methodsA systematic search was conducted in PubMed, Web of Science, Scopus, and Cochrane Library until March 2023 for meta-analyses evaluating the effects of probiotics, prebiotics, and synbiotics on patients with NAFLD. Random-effect models, sensitivity analysis, and subgroup analysis were employed.

resultsGut microbial therapy significantly decreased HOMA-IR (ES: -0.41; 95%CI: -0.52, -0.31; P < 0.001) and FI (ES: -0.59; 95%CI: -0.77, -0.41; P < 0.001). However, no significant effect was observed on FBS (ES: -0.17; 95%CI: -0.36, 0.02; P = 0.082). Subgroup analysis revealed prebiotics had the most potent effect on HOMA-IR, followed by probiotics and synbiotics. For FI, synbiotics had the most substantial effect, followed by prebiotics and probiotics.

conclusionProbiotics, prebiotics, and synbiotics administration significantly reduced FI and HOMA-IR, but no significant effect was observed on FBS.

Indexed as

Gastrointestinal MicrobiomeGlycemic IndexInsulin ResistanceNon-alcoholic Fatty Liver DiseasePrebioticsProbioticsSynbioticsBlood GlucoseDiabetes Mellitus, Type 2HumansInsulinMeta-Analysis as TopicBlood GlucoseInsulinPrebiotics

Identifiers

PMID38729941
PMCPMC11087547

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.